SCHEMBL3011091

SCHEMBL3011091

N#CC1(c2ccccc2)CCC(OCC2CC2)(c2cc(-c3ccccc3)nn2CC2CC2)CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 1/20 0.38
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
MAPT P10636 1/20 0.35
HPGD P15428 1/20 0.35
ALOX15 P16050 1/20 0.35
MAPK1 P28482 1/20 0.35
MCL1 Q07820 1/20 0.35
HSD17B10 Q99714 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
JAK2 O60674 1/20 0.35
JAK1 P23458 1/20 0.35
PRNP P04156 1/20 0.35
PTGIR P43119 1/20 0.35
OPRL1 P41146 2/20 0.34
OPRM1 P35372 1/20 0.34
CRHR1 P34998 1/20 0.32
CRHR2 Q13324 1/20 0.32
HTR5A P47898 1/20 0.32
KDM1A O60341 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3011085 1.00 GRM2 (0.38) GRM2KDM4EALDH1A1MAPTHPGD
SCHEMBL3011088 1.00 GRM2 (0.38) GRM2KDM4EALDH1A1MAPTHPGD
SCHEMBL3011863 0.84 GRM2 (0.40) GRM2JAK2JAK1OPRL1OPRM1
SCHEMBL3011867 0.84 GRM2 (0.40) GRM2JAK2JAK1OPRL1OPRM1
SCHEMBL3011869 0.84 GRM2 (0.40) GRM2JAK2JAK1OPRL1OPRM1
SCHEMBL3027200 0.83 GRM2 (0.38) GRM2JAK2JAK1PRNPPTGIR
SCHEMBL3019076 0.83 CRHR1 (0.37) ALDH1A1PRNPPTGIRCRHR1CRHR2
SCHEMBL3027205 0.83 GRM2 (0.38) GRM2JAK2JAK1PRNPPTGIR
SCHEMBL3027203 0.83 GRM2 (0.38) GRM2JAK2JAK1PRNPPTGIR
SCHEMBL3019074 0.83 CRHR1 (0.37) ALDH1A1PRNPPTGIRCRHR1CRHR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2164825-B1 DI(HETERO)ARYLCYCLOHEXANE DERIVATIVES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM SANOFI SA (FR) 2014-04-30 EP disclosed
US-8076324-B2 Di(hetero)arylcyclohexane derivatives, their preparation, their use and pharmaceutical compositions comprising them SANOFI-AVENTIS (FR) 2011-12-13 US disclosed
US-20100204206-A1 Di(hetero)arylcyclohexane derivatives, their preparation, their use and pharmaceutical compositions comprising them SANOFI-AVENTIS (FR) 2010-08-12 US disclosed
EP-2164825-A1 DI(HETERO)ARYLCYCLOHEXANE DERIVATIVES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM Sanofi-Aventis (FR) 2010-03-24 EP disclosed
WO-2008148468-A1 DI(HETERO)ARYLCYCLOHEXANE DERIVATIVES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM SANOFI-AVENTIS (FR) 2008-12-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100204206-A1 Di(hetero)arylcyclohexane derivatives, their preparation, their use and pharmaceutical compositions comprising them ATP2A1, ATP2A2, RYR2 GRM2 2008/4885KDM4E 2822/4885ALDH1A1 1662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.